- Home
- COYA vs EQ Comparison
COYA vs EQ Comparison
Compare COYA & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | EQ |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.8M | 129.0M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | COYA | EQ |
|---|---|---|
| Price | $4.28 | $2.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $15.80 | $8.00 |
| AVG Volume (30 Days) | 266.7K | ★ 1.0M |
| Earning Date | 05-08-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,945,753.00 | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $763.10 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 123.57 | N/A |
| 52 Week Low | $3.71 | $0.37 |
| 52 Week High | $7.75 | $3.54 |
Technical Indicators
Market Signals| Indicator | COYA | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 33.98 | 42.71 |
| Support Level | $3.90 | $2.36 |
| Resistance Level | $5.18 | $2.61 |
| Average True Range (ATR) | 0.34 | 0.24 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 2.99 | 18.87 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.